Xuantai Pharmaceutical announced that it recently received notification from the U.S. Food and Drug Administration (FDA) that its Abbreviated New Drug Application (ANDA) for sitagliptin metformin extended-release tablets has been tentatively approved. Developed by Merck Sharp & HOEME, the drug was approved for marketing in the United States in February 2012 and is indicated for improving glycemic control in adults with type 2 diabetes. Sitagliptin metformin extended-release tablets are already commercially available in China.